WA-KYMETA
15.11.2017 14:02:16 CET | Business Wire | Press release
Redmond-based Kymeta—the communications company making good on the promise of global mobile connectivity—set out on a two-week trek across America in its connected Toyota RAV4 to provide a rigorous, real-world proving ground for its widely anticipated KĀLO™ internet service. KĀLO services will deliver a new mobile satellite internet service that will make mobile high-throughput internet access available and easy to buy. The KĀLO Trek Across America will begin in Washington, D.C. and wind through the country, covering over 7,000 miles, and culminating in a homecoming event at the Kymeta campus in Washington state on November 27.
Powered by the IntelsatOne® Flex network, Kymeta KĀLO services will provide high-bandwidth mobile satellite internet access to industries that require connectivity on the move like military, news reporting, first responders, construction, trains, buses and more. KĀLO services, when paired with Kymeta™ KyWay™ terminals and mTennau7 ASMs, will connect places and fixed and mobile platforms that have traditionally had limited or no connectivity at all.
“Kymeta is taking its connected car across the country to put the network through the paces,” said Dushyant Sukhija, SVP and General Manager, KĀLO Business Unit, Kymeta. “When launched, KĀLO mobile internet services will mark a revolutionary change in the way satellite services are purchased and supplied, making it as simple as purchasing a cell phone plan. The launch of Kymeta KĀLO services will usher in changes in the way businesses get work done: on the move, from everyday vehicles, in even the most difficult to reach industries and areas of the world.”
The KĀLO Trek Across America tells another important story: the possibility of a truly connected car is now a reality. Kymeta’s Toyota RAV4 will remain connected throughout its U.S. journey, conducting live streams and updates from the road. “As innovations in satellite connectivity come to market, such as our Intelsat EpicNG high-throughput satellites, we are unlocking new applications. Industries recognize that connected cars and other vehicles will enable new services and opportunities for increased efficiency; traditional networks can’t support that growth today,” said Mark Rasmussen, VP and General Manager, Mobility, Intelsat. “Leveraging our global IntelsatOne Flex network, our partnership with Kymeta will bring KĀLO internet services to every corner of the U.S., and eventually every region of the world. This plan aligns to our goal: make connectivity accessible to everyone, everything, everywhere, at any time. Kymeta KĀLO services are proof that connectivity can reach every industry, large and small, and be used for any application, no matter where you are, especially while you’re on the move.”
For a map of the KĀLO Trek Across America destinations, and to follow along as the team gives updates on the route home, visit KĀLO Trek online .
About Kymeta
What’s the missing link to connecting billions of people to high-speed mobile access? Antennas. And Kymeta offers the world’s only commercially viable electronically scanning satellite antennas and terminals. Kymeta antennas and terminals deliver high-throughput communications for land, sea and air, making mobile connectivity as available as a view of the sky. Plus, the world’s largest satellite operator, Intelsat, has joined forces with Kymeta to deliver KĀLO™ global access services that combine with Kymeta antennas and terminals to provide revolutionary mobile connectivity. Without Kymeta mTenna™ technology, connecting and staying connected to all those new satellites while on the move will be difficult, if not impossible.
If it moves, Kymeta will keep it connected. Anywhere.
For more information, visit kymetacorp.com and KALO.net .
View source version on businesswire.com: http://www.businesswire.com/news/home/20171115005354/en/
Contact:
Business Inquiries for Kymeta:
Kymeta Corporation
Lisa
Dreher, +1 425-658-8724
Director of Marketing
ldreher@kymetacorp.com
or
Media
Inquiries for Kymeta:
The Summit Group
Amy Oliver, +1
801-990-1185
Mobile: +1 801-783-9067
PR/Content Manager
aoliver@summitslc.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
